ResearcherAzienda USL di BolognaActive in the last 2 years
Sirio Fiorino
Matched on ORCID iD 0000-0001-5755-2197; OpenAlex author ID A5007849093. Sources: OpenAlex.
Their work
- Papers
- 9
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2012: 1 paper · 2013: 3 papers · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 9
- Focus on the Interactive Cooperation Among Mechanotransduction and Biochemical Processes in Pancreatic Ductal Adenocarcinoma Development and Possible Adjuvant … Co-author DOI 10.3390/cancers18121932↗
- Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel. Co-author DOI 10.3390/diagnostics12051058↗
- Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study. Co-author DOI 10.1007/s11033-020-05763-2↗
- Matricellular proteins and survival in patients with pancreatic cancer: A systematic review. Co-author DOI 10.1016/j.pan.2017.11.001↗
- Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. Co-author DOI 10.3233/cbm-170464↗
- Association between hepatitis B or hepatitis C virus infection and risk of pancreatic adenocarcinoma development: a systematic review and meta-analysis. Co-author DOI 10.1016/j.pan.2013.01.005↗
- HBV and HCV infection and pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/s1499-3872(13)60090-9↗
- HBV- and HCV-related infections and risk of pancreatic cancer. Co-author DOI 10.6092/1590-8577/1948↗
- Hepatitis B and C virus infections as possible risk factor for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.mehy.2012.08.008↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Elio Jovine · 8 shared papers, 2012–2026 · strength 0.71
- Paper Focus on the Interactive Cooperation Among Mechanotransduction and Biochemical Processes in Pancreatic Ductal Adenocarc… DOI 10.3390/cancers18121932↗
- Paper Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multi… DOI 10.3390/diagnostics12051058↗
- Paper Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study. DOI 10.1007/s11033-020-05763-2↗
- Dario de Biase · 5 shared papers, 2018–2026 · strength 0.60
- Paper Focus on the Interactive Cooperation Among Mechanotransduction and Biochemical Processes in Pancreatic Ductal Adenocarc… DOI 10.3390/cancers18121932↗
- Paper Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multi… DOI 10.3390/diagnostics12051058↗
- Paper Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study. DOI 10.1007/s11033-020-05763-2↗
- Michele Masetti · 6 shared papers, 2012–2022 · strength 0.39
- Paper Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multi… DOI 10.3390/diagnostics12051058↗
- Paper Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study. DOI 10.1007/s11033-020-05763-2↗
- Paper Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. DOI 10.3233/cbm-170464↗
- Giovanni Tallini · 3 shared papers, 2018–2022 · strength 0.28
- Paper Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multi… DOI 10.3390/diagnostics12051058↗
- Paper Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study. DOI 10.1007/s11033-020-05763-2↗
- Paper Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. DOI 10.3233/cbm-170464↗
- Maddalena Zippi · 1 shared paper, 2026 · strength 0.27
- Michela Visani · 3 shared papers, 2018–2020 · strength 0.21
- Paper Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study. DOI 10.1007/s11033-020-05763-2↗
- Paper Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. DOI 10.3233/cbm-170464↗
- Paper Matricellular proteins and survival in patients with pancreatic cancer: A systematic review. DOI 10.1016/j.pan.2017.11.001↗
- Carlo Fabbri · 3 shared papers, 2018–2020 · strength 0.21
- Paper Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study. DOI 10.1007/s11033-020-05763-2↗
- Paper Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. DOI 10.3233/cbm-170464↗
- Paper Matricellular proteins and survival in patients with pancreatic cancer: A systematic review. DOI 10.1016/j.pan.2017.11.001↗
- Deborah Malvi · 1 shared paper, 2022 · strength 0.12
- Mariacristina Di Marco · 1 shared paper, 2022 · strength 0.12
- Chiara Birtolo · 1 shared paper, 2018 · strength 0.05
- Nicola Zanini · 1 shared paper, 2013 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.